Bishop Barron, U.S. Bishops Condemn FDA’s Approval of First OTC Birth Control Pill
The U.S. bishops have long advocated against FDA nonprescription approval of Opill because of potential harmful side effects.
Bishop Robert Barron of Winona-Rochester, Minnesota, unequivocally condemned the FDA’s approval of the first over-the-counter oral contraceptive “Opill” in a short but strongly worded statement released Thursday on behalf of the U.S. Conference of Catholic Bishops.
The use of artificial contraceptives of any kind is directly contradictory to Catholic moral teaching and is “intrinsically evil,” according to paragraph 2370 of the Catechism of the Catholic Church.
As head of the U.S. bishops’ Laity, Marriage, Family Life, and Youth Committee, Bishop Barron decried the FDA’s latest action as a violation of the Hippocratic Oath, a vow health providers take to “do no harm.”
“Allowing this hormonal contraception to be dispensed ‘over the counter’ — without the supervision of a doctor and contrary to the mounting evidence of many harmful side effects — violates the Hippocratic Oath by putting the health of women at grave risk,” Bishop Barron said.
“This action by a government entity flies in the face of responsible medical practice and concerns for women’s health,” Barron said, adding that “claims that the benefits of this action outweigh the risks are unfounded, especially in light of strong evidence of the many harmful risks of hormonal contraception to women’s health.”
Opill, a progestin (synthetic hormone)-based drug produced by Perrigo, is the first over-the-counter oral contraceptive to receive FDA approval. Under the FDA’s new guidelines, individuals can obtain and use Opill without the guidance or supervision of a doctor.
The drug’s approval is likely to lead to increased use of contraceptives. With Opill set to be easily accessible and available in retail drugstores in early 2024, it is expected to be heavily used by young women, even minors.
According to Perrigo, Opill is safe for all ages, so long as menstruation has begun. However, the AP reported the FDA had concerns about flaws in Perrigo’s research and testing. Nevertheless, the FDA announced Opill had received official approval on July 13. There is no age restriction on Opill’s use.
The U.S. bishops have long advocated against FDA nonprescription approval of Opill because of potential harmful side effects. When the FDA was still considering the matter in May, Bishop Barron strongly urged the administration to reject Perrigo’s Opill approval request.
“Fertility is a gift, not a disease. Contraceptives exist to suppress the healthy functions of human reproduction,” Bishop Barron said in a May statement.
The National Catholic Bioethics Center, joined by the U.S. bishops, the Catholic Medical Association, and the National Association of Catholic Nurses, sent a letter to the FDA in November 2022 opposing Opill’s nonprescription availability because it presented numerous negative side effects including organ failure, cardiovascular disease, and neurological issues.
- abortion pill